Harry Sokol

List of Publications by Citations

230 papers	19,301 citations	64 h-index	136 g-index
275 ext. papers	25,596 ext. citations	9.3 avg, IF	7.09 L-index

#	Paper	IF	Citations
230	Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 16731-6	11.5	2742
229	Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biology*, **2012**, 13, R79	18.3	1668
228	Low counts of Faecalibacterium prausnitzii in colitis microbiota. *Inflammatory Bowel Diseases*, **2009**, 15, 1183-9	4.5	822
227	Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. *Cell Host and Microbe*, **2018**, 23, 716-724	23.4	682
226	CARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands. *Nature Medicine*, **2016**, 22, 598-605	50.5	628
225	Faecalibacterium prausnitzii and human intestinal health. *Current Opinion in Microbiology*, **2013**, 16, 255-61	7.9	576
224	Fungal microbiota dysbiosis in IBD. *Gut*, **2017**, 66, 1039-1048	19.2	562
223	European consensus conference on faecal microbiota transplantation in clinical practice. *Gut*, **2017**, 66, 569-580	19.2	520
222	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. *Gut*, **2013**, 62, 531-9	19.2	422
221	A microbial signature for Crohn's disease. *Gut*, **2017**, 66, 813-822	19.2	409
220	Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn's disease. *Gut*, **2016**, 65, 415-425	19.2	396
219	Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects. *Immunity*, **2016**, 45, 931-943	32.3	376
218	Specificities of the fecal microbiota in inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2006**, 12, 106-11	4.5	322
217	Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 223-237	24.2	318
216	Functional Characterization of Novel Strains Isolated from Healthy Volunteers: A Step Forward in the Use of as a Next-Generation Probiotic. *Frontiers in Microbiology*, **2017**, 8, 1226	5.7	191
215	Impaired Aryl Hydrocarbon Receptor Ligand Production by the Gut Microbiota Is a Key Factor in Metabolic Syndrome. *Cell Metabolism*, **2018**, 28, 737-749.e4	24.6	188
214	Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. *Annals of the Rheumatic Diseases*, **2017**, 76, 1614-1622	2.4	173

213	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. *Gut*, **2019**, 68, 2111-2121	19.2	169
212	Aryl hydrocarbon receptor and intestinal immunity. *Mucosal Immunology*, **2018**, 11, 1024-1038	9.2	168
211	Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. *Neurogastroenterology and Motility*, **2012**, 24, 513-20, e246-7	4	164
210	Analysis of bacterial bowel communities of IBD patients: what has it revealed?. *Inflammatory Bowel Diseases*, **2008**, 14, 858-67	4.5	163
209	Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. *Nature Communications*, **2018**, 9, 2802	17.4	160
208	Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. *Journal of Crohnis and Colitis*, **2016**, 10, 296-305	1.5	156
207	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1593-1601.e2	6.9	141
206	The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. *Inflammatory Bowel Diseases*, **2014**, 20, 417-30	4.5	139
205	Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. *Gut*, **2010**, 59, 1363-8	19.2	132
204	Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii. *MBio*, **2015**, 6,	7.8	128
203	Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. *BMC Microbiology*, **2015**, 15, 67	4.5	128
202	The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. *Nature Reviews Gastroenterology and Hepatology*, **2019**, 16, 331-345	24.2	128
201	Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. *Nature Medicine*, **2018**, 24, 1113-1120	50.5	121
200	Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. *Scientific Reports*, **2016**, 6, 18507	4.9	119
199	Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease. *Inflammatory Bowel Diseases*, **2014**, 20, 978-86	4.5	117
198	Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. *Journal of Clinical Microbiology*, **2006**, 44, 3172-7	9.7	113
197	Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). *Journal of Crohnis and Colitis*, **2014**, 8, 31-44	1.5	111
196	Card9 mediates intestinal epithelial cell restitution, T-helper 17 responses, and control of bacterial infection in mice. *Gastroenterology*, **2013**, 145, 591-601.e3	13.3	107

195	Fecal Microbiota Transplantation is Safe and Efficacious for Recurrent or Refractory Clostridium difficile Infection in Patients with Inflammatory Bowel Disease. *Inflammatory Bowel Diseases*, **2016**, 22, 2402-9	4.5	106
194	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. *American Journal of Gastroenterology*, **2017**, 112, 337-345	0.7	104
193	The intestinal microbiota in inflammatory bowel diseases: time to connect with the host. *Current Opinion in Gastroenterology*, **2010**, 26, 327-31	3	101
192	Gut microbiota-derived metabolites as central regulators in metabolic disorders. *Gut*, **2021**, 70, 1174-1182	19.2	101
191	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. *Gut*, **2019**, 68, 1504-1515	19.2	100
190	Probiotic Strain BL23 Prevents Colitis-Associated Colorectal Cancer. *Frontiers in Immunology*, **2017**, 8, 1553	8.4	97
189	Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. *International Journal of Food Microbiology*, **2010**, 144, 35-41	5.8	97
188	Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. *Gut Microbes*, **2015**, 6, 1-9	8.8	95
187	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. *Gut*, **2014**, 63, 1416-23	19.2	94
186	Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study. *Microbiome*, **2020**, 8, 12	16.6	89
185	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 310-321	6.1	85
184	Mucosa-associated microbiota dysbiosis in colitis associated cancer. *Gut Microbes*, **2018**, 9, 131-142	8.8	83
183	Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 430-432	18.8	82
182	Plexitis as a predictive factor of early postoperative clinical recurrence in Crohn's disease. *Gut*, **2009**, 58, 1218-25	19.2	82
181	Ecology and metabolism of the beneficial intestinal commensal bacterium Faecalibacterium prausnitzii. *Gut Microbes*, **2014**, 5, 146-51	8.8	81
180	Factors affecting outcomes in Crohn's disease over 15 years. *Gut*, **2012**, 61, 1140-5	19.2	81
179	CD4CD8□□ lymphocytes, a novel human regulatory T cell subset induced by colonic bacteria and deficient in patients with inflammatory bowel disease. *PLoS Biology*, **2014**, 12, e1001833	9.7	78
178	Toll-like receptor 2 is critical for induction of Reg3 beta expression and intestinal clearance of Yersinia pseudotuberculosis. *Gut*, **2009**, 58, 771-6	19.2	78

177	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2012**, 18, 2063-71	4.5	77
176	Enterobacteriaceae are essential for the modulation of colitis severity by fungi. *Microbiome*, **2018**, 6, 152	16.6	77
175	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. *JAMA - Journal of the American Medical Association*, **2019**, 321, 773-785	27.4	75
174	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. *World Journal of Gastroenterology*, **2008**, 14, 3497-503	5.6	71
173	Gut fungal microbiota: the Yin and Yang of inflammatory bowel disease. *Inflammatory Bowel Diseases*, **2015**, 21, 656-65	4.5	70
172	Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. *Cell Metabolism*, **2015**, 22, 460-71	24.6	70
171	Interplay between bile acid metabolism and microbiota in irritable bowel syndrome. *Neurogastroenterology and Motility*, **2016**, 28, 1330-40	4	70
170	Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection. *Cell Reports*, **2020**, 32, 107915	10.6	68
169	Gut Microbiota-Stimulated Innate Lymphoid Cells Support Defensin 14 Expression in Pancreatic Endocrine Cells, Preventing Autoimmune Diabetes. *Cell Metabolism*, **2018**, 28, 557-572.e6	24.6	67
168	Bacterial protein signals are associated with Crohn's disease. *Gut*, **2014**, 63, 1566-77	19.2	67
167	Microorganisms linked to inflammatory bowel disease-associated dysbiosis differentially impact host physiology in gnotobiotic mice. *ISME Journal*, **2016**, 10, 460-77	11.9	66
166	Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. *Alimentary Pharmacology and Therapeutics*, **2009**, 29, 1106-13	6.1	64
165	Clinical, serological and genetic predictors of inflammatory bowel disease course. *World Journal of Gastroenterology*, **2012**, 18, 3806-13	5.6	64
164	Impact of probiotics on risk factors for cardiovascular diseases. A review. *Critical Reviews in Food Science and Nutrition*, **2014**, 54, 175-89	11.5	63
163	Gastrointestinal involvement and manifestations in systemic mastocytosis. *Inflammatory Bowel Diseases*, **2010**, 16, 1247-53	4.5	63
162	Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia. *Nature Communications*, **2014**, 5, 4675	17.4	62
161	Fungi participate in the dysbiosis of gut microbiota in patients with primary sclerosing cholangitis. *Gut*, **2020**, 69, 92-102	19.2	62
160	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. *Alimentary Pharmacology and Therapeutics*, **2018**, 47, 485-493	6.1	61

159	Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria. *Haematologica*, **2019**, 104, 1682-1688	6.6	60
158	Effects of light smoking consumption on the clinical course of Crohn's disease. *Inflammatory Bowel Diseases*, **2009**, 15, 734-41	4.5	60
157	Crohn's disease of the vulva. *Journal of Crohnis and Colitis*, **2014**, 8, 563-70	1.5	58
156	Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. *United European Gastroenterology Journal*, **2020**, 8, 303-313	5.3	58
155	Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. *Gut*, **2020**, 69, 1555-1563	19.2	57
154	Phages infecting Faecalibacterium prausnitzii belong to novel viral genera that help to decipher intestinal viromes. *Microbiome*, **2018**, 6, 65	16.6	57
153	Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. *American Journal of Gastroenterology*, **2010**, 105, 2405-11	0.7	57
152	Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. *Gut*, **2009**, 58, 1427-36	19.2	54
151	Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. *Human Vaccines and Immunotherapeutics*, **2014**, 10, 1611-21	4.4	53
150	Long-term outcome of patients with Crohn's disease who respond to azathioprine. *Clinical Gastroenterology and Hepatology*, **2013**, 11, 389-94	6.9	52
149	The impact of cytomegalovirus reactivation and its treatment on the course of inflammatory bowel disease. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 712-20	6.1	51
148	The Gut Microbiota at the Service of Immunometabolism. *Cell Metabolism*, **2020**, 32, 514-523	24.6	50
147	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection. *Gut Microbes*, **2018**, 9, 55-60	8.8	49
146	Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models. *Scientific Reports*, **2016**, 6, 19399	4.9	48
145	Gastrointestinal manifestations in mastocytosis: a study of 83 patients. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 866-73.e1-3	11.5	47
144	Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing. *Science*, **2020**, 368, 186-189	33.3	46
143	Anti-inflammatory properties of dairy lactobacilli. *Inflammatory Bowel Diseases*, **2012**, 18, 657-66	4.5	46
142	Fecal microbiota transplantation in inflammatory bowel disease: the quest for the holy grail. *Mucosal Immunology*, **2016**, 9, 1360-1365	9.2	46

141	Clostridium difficile infection in acute flares of inflammatory bowel disease: A prospective study. *Digestive and Liver Disease*, **2017**, 49, 643-646	3.3	45
140	Skews Human DC to Prime IL10-Producing T Cells Through TLR2/6/JNK Signaling and IL-10, IL-27, CD39, and IDO-1 Induction. *Frontiers in Immunology*, **2019**, 10, 143	8.4	45
139	Identification of novel anti-inflammatory probiotic strains isolated from pulque. *Applied Microbiology and Biotechnology*, **2016**, 100, 385-396	5.7	45
138	Aryl hydrocarbon receptor ligand production by the gut microbiota is decreased in celiac disease leading to intestinal inflammation. *Science Translational Medicine*, **2020**, 12,	17.5	44
137	Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. *Gut*, **2020**, 69, 462-472	19.2	44
136	Faecal microbiota transplantation in recurrent Clostridium difficile infection: Recommendations from the French Group of Faecal microbiota Transplantation. *Digestive and Liver Disease*, **2016**, 48, 242-7	3.3	41
135	Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population. *PLoS Genetics*, **2018**, 14, e1007329	6	41
134	p40phox expression regulates neutrophil recruitment and function during the resolution phase of intestinal inflammation. *Journal of Immunology*, **2012**, 189, 3631-40	5.3	41
133	Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study in France. *Clinical Infectious Diseases*, **2017**, 64, 767-775	11.6	38
132	Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. *Inflammatory Bowel Diseases*, **2013**, 19, 2084-90	4.5	38
131	Changes in the LÉmann Index Values During the First Years of Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1633-40.e3	6.9	36
130	SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. *Gut Microbes*, **2021**, 13, 1-19	8.8	36
129	Complications and surgery in the inflammatory bowel diseases biological era. *Current Opinion in Gastroenterology*, **2014**, 30, 378-84	3	35
128	Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. *Gut*, **2007**, 56, 152-4	19.2	35
127	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 924-932	6.1	35
126	Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. *Frontiers in Microbiology*, **2016**, 7, 608	5.7	34
125	Probiotics and antibiotics in IBD. *Digestive Diseases*, **2014**, 32 Suppl 1, 10-7	3.2	33
124	Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. *Inflammatory Bowel Diseases*, **2012**, 18, 1101-11	4.5	32

123	Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: a retrospective assessment. *Digestive and Liver Disease*, **2014**, 46, 1086-92	3.3	31
122	Tryptophan Metabolism as a Pharmacological Target. *Trends in Pharmacological Sciences*, **2021**, 42, 60-73	13.2	31
121	New Insights into the Diversity of the Genus. *Frontiers in Microbiology*, **2017**, 8, 1790	5.7	30
120	Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. *Inflammatory Bowel Diseases*, **2015**, 21, 60-70	4.5	28
119	Features of Autoimmune Pancreatitis Associated With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 59-67	6.9	28
118	Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease?. *Molecular Nutrition and Food Research*, **2008**, 52, 906-12	5.9	27
117	The microbiota: an underestimated actor in radiation-induced lesions?. *Gut*, **2018**, 67, 1-2	19.2	25
116	Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2016**, 44, 1102-1113	6.1	25
115	Card9 mediates susceptibility to intestinal pathogens through microbiota modulation and control of bacterial virulence. *Gut*, **2018**, 67, 1836-1844	19.2	25
114	Genetic effects on the commensal microbiota in inflammatory bowel disease patients. *PLoS Genetics*, **2019**, 15, e1008018	6	24
113	Baseline microbiota composition modulates antibiotic-mediated effects on the gut microbiota and host. *Microbiome*, **2019**, 7, 111	16.6	24
112	Recipient factors in faecal microbiota transplantation: one stool does not fit all. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 503-513	24.2	24
111	Expression of CCR6 and CXCR6 by Gut-Derived CD4/CD8 T-Regulatory Cells, Which Are Decreased in Blood Samples From Patients With Inflammatory Bowel Diseases. *Gastroenterology*, **2018**, 155, 1205-1217	13.3	24
110	Gut microbiota: Beyond metagenomics, metatranscriptomics illuminates microbiome functionality in IBD. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 193-194	24.2	23
109	Using murine colitis models to analyze probiotics-host interactions. *FEMS Microbiology Reviews*, **2017**, 41, S49-S70	15.1	23
108	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. *Gut*, **2021**, 70, 1299-1308	19.2	23
107	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. *Alimentary Pharmacology and Therapeutics*, **2017**, 46, 1077-1084	6.1	22
106	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. *Digestive Diseases*, **2015**, 33 Suppl 1, 105-112	3.2	22

105	Butyrate mediates anti-inflammatory effects of in intestinal epithelial cells through. *Gut Microbes*, **2020**, 12, 1-16	8.8	22
104	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. *Frontiers in Microbiology*, **2018**, 9, 565	5.7	21
103	Inter-kingdom effect on epithelial cells of the N-Acyl homoserine lactone 3-oxo-C12:2, a major quorum-sensing molecule from gut microbiota. *PLoS ONE*, **2018**, 13, e0202587	3.7	21
102	Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series. *Journal of Allergy and Clinical Immunology*, **2013**, 132, 997-1000.e1-4	11.5	20
101	The enemy from within: a prophage of Roseburia intestinalis systematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition. *ISME Journal*, **2020**, 14, 771-787	11.9	20
100	T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence. *Gut*, **2019**, 68, 1961-1970	19.2	19
99	The presence of the anti-inflammatory protein MAM, from Faecalibacterium prausnitzii, in the intestinal ecosystem. *Gut*, **2016**, 65, 882	19.2	19
98	Reporting guidelines for human microbiome research: the STORMS checklist. *Nature Medicine*, **2021**, 27, 1885-1892	50.5	19
97	A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group. *United European Gastroenterology Journal*, **2021**, 9, 229-247	5.3	19
96	Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation via Interleukin-22 Modulation. *Frontiers in Immunology*, **2020**, 11, 144	8.4	18
95	Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. *Digestive Diseases*, **2009**, 27, 375-81	3.2	18
94	Gut microbiota-derived short-chain fatty acids regulate IL-17 production by mouse and human intestinal □T´cells. *Cell Reports*, **2021**, 36, 109332	10.6	18
93	Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation. *Mucosal Immunology*, **2018**, 11, 1181-1190	9.2	17
92	Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. *Journal of Crohnis and Colitis*, **2014**, 8, 819-24	1.5	17
91	Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease. *Inflammatory Bowel Diseases*, **2009**, 15, 1449-51	4.5	17
90	Linking Strain Engraftment in Fecal Microbiota Transplantation With Maintenance of Remission in Crohn's Disease. *Gastroenterology*, **2020**, 159, 2193-2202.e5	13.3	16
89	Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen. *International Journal of Obesity*, **2019**, 43, 428-431	5.5	16
88	Diet-Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice. *Hepatology Communications*, **2018**, 2, 1533-1549	6	16

87	Biopsy-proven anuric acute tubular necrosis associated with vancomycin and one dose of aminoside. *Nephrology Dialysis Transplantation*, **2004**, 19, 1921-2	4.3	15
86	Intestinal dysbiosis in inflammatory bowel disease associated with primary immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 775-778.e6	11.5	15
85	Postbiotics - when simplification fails to clarify. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 825-826	24.2	15
84	Fecal microbiota transplantation in gastrointestinal disorders: time for precision medicine. *Genome Medicine*, **2020**, 12, 58	14.4	14
83	Crypt abscess-associated microbiota in inflammatory bowel disease and acute self-limited colitis. *World Journal of Gastroenterology*, **2010**, 16, 583-7	5.6	14
82	Drug Mimicry: Promiscuous Receptors PXR and AhR, and Microbial Metabolite Interactions in the Intestine. *Trends in Pharmacological Sciences*, **2020**, 41, 900-908	13.2	14
81	Validation of a global quantitative analysis methodology of tryptophan metabolites in mice using LC-MS. *Talanta*, **2019**, 195, 593-598	6.2	14
80	Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease. *PLoS ONE*, **2018**, 13, e0201991	3.7	14
79	Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease. *Journal of Crohnis and Colitis*, **2015**, 9, 349-55	1.5	13
78	A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. *Alimentary Pharmacology and Therapeutics*, **2020**, 51, 553-564	6.1	13
77	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. *BMJ Open*, **2018**, 8, e021037	3	12
76	Sera from patients with Crohn's disease break bacterial lipopolysaccharide tolerance of human intestinal epithelial cells via MD-2 activity. *Innate Immunity*, **2010**, 16, 381-90	2.7	11
75	Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. *Inflammatory Bowel Diseases*, **2010**, 16, 362-3	4.5	11
74	Appendicitis, not appendectomy, is protective against ulcerative colitis, both in the general population and first-degree relatives of patients with IBD. *Inflammatory Bowel Diseases*, **2010**, 16, 356-7	4.5	11
73	Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. *PLoS ONE*, **2016**, 11, e0157191	3.7	11
72	Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. *Therapeutic Advances in Gastroenterology*, **2020**, 13, 1756284820946904	4.7	10
71	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. *Cancer Immunology Research*, **2020**, 8, 1407-1425	12.5	10
70	Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 141-149.e2	6.9	10

69	Caspase recruitment domain 9, microbiota, and tryptophan metabolism: dangerous liaisons in inflammatory bowel diseases. *Current Opinion in Clinical Nutrition and Metabolic Care*, **2017**, 20, 243-247	3.8	9
68	Microbiota in digestive cancers: our new partner?. *Carcinogenesis*, **2017**, 38, 1157-1166	4.6	9
67	Crosstalk between the hepatologist and the cardiologist: a future place for the lithocholic acid as a coronary atheroma risk factor?. *Hepatology*, **2012**, 56, 2426	11.2	9
66	Acute cryptosporidiosis as a cause of sudden recurrence of digestive symptoms in patients with Crohn's disease. *Journal of Crohnis and Colitis*, **2010**, 4, 669-70	1.5	9
65	A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1602-1610.e1	6.9	8
64	Oral delivery of pancreatitis-associated protein by Lactococcus lactis displays protective effects in dinitro-benzenesulfonic-acid-induced colitis model and is able to modulate the composition of the microbiota. *Environmental Microbiology*, **2019**, 21, 4020-4031	5.2	8
63	Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice. *PLoS ONE*, **2017**, 12, e0184624	3.7	8
62	Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug. *United European Gastroenterology Journal*, **2019**, 7, 1408-1410	5.3	8
61	The regenerating family member 3 instigates IL-17A-mediated neutrophil recruitment downstream of NOD1/2 signalling for controlling colonisation resistance independently of microbiota community structure. *Gut*, **2019**, 68, 1190-1199	19.2	8
60	Inhibitory Effect of Ursodeoxycholic Acid on Germination Is Insufficient to Prevent Colitis: A Study in Hamsters and Humans. *Frontiers in Microbiology*, **2018**, 9, 2849	5.7	8
59	Fecal Microbiota Transplantation: Do We Need Harmonization?. *Clinical Infectious Diseases*, **2017**, 64, 1292	11.6	7
58	Differences in epidemiological features between ulcerative colitis and Crohn's disease: The early life-programmed versus late dysbiosis hypothesis. *Medical Hypotheses*, **2018**, 115, 19-21	3.8	7
57	Risk of serious infection in healthcare workers with inflammatory bowel disease: a case-control study of the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID). *Alimentary Pharmacology and Therapeutics*, **2018**, 48, 713-722	6.1	7
56	Thalidomide as a treatment for refractory CGD colitis. *American Journal of Gastroenterology*, **2009**, 104, 1069	0.7	7
55	Pure ileal Crohn's disease without colonic involvement after a long ileo-colonic anastomosis (Lester Martin Procedure) for Hirschsprung's disease: an argument favoring a specific sensitivity of the ileum in a subset of patients with Crohn's disease. *Inflammatory Bowel Diseases*, **2007**, 13, 243-4	4.5	7
54	Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 620-627.e1	6.9	7
53	Nancy Index Scores of Chronic Inflammatory Bowel Disease Activity Associate With Development of Colorectal Neoplasia. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 150-157.e1	6.9	7
52	Alteration of the gut microbiota following SARS-CoV-2 infection correlates with disease severity in hamsters.. *Gut Microbes*, **2022**, 14, 2018900	8.8	7

51	A necessary discussion after transmission of multidrug-resistant organisms through faecal microbiota transplantations. *Lancet Infectious Diseases, The*, **2019**, 19, 1161-1162	25.5	6
50	Unilateral carotid granulomatous arteritis and Crohn's disease. *Revue Neurologique*, **2010**, 166, 542-6	3	6
49	Tryptophan metabolites get the gut moving. *Cell Host and Microbe*, **2021**, 29, 145-147	23.4	6
48	Specific changes in faecal microbiota are associated with familial Mediterranean fever. *Annals of the Rheumatic Diseases*, **2019**, 78, 1398-1404	2.4	5
47	Beneficial effects of exclusive enteral nutrition in Crohn's disease are not mediated by Faecalibacterium prausnitzii. *Inflammatory Bowel Diseases*, **2014**, 20, E18	4.5	5
46	Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome. *American Journal of Kidney Diseases*, **2006**, 47, 1072-4	7.4	5
45	Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	5
44	The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey. *Lancet Regional Health - Europe, The*, **2021**, 9, 100181		5
43	Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease. *Microbiome*, **2021**, 9, 176	16.6	5
42	Microbiota in´neuroinflammation´and´synaptic dysfunction: a focus on Alzheimer's disease.. *Molecular Neurodegeneration*, **2022**, 17, 19	19	5
41	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. *Journal of Crohnis and Colitis*, **2020**, 14, 896-903	1.5	4
40	An image-based genetic assay identifies genes in T1D susceptibility loci controlling cellular antiviral immunity in mouse. *PLoS ONE*, **2014**, 9, e108777	3.7	4
39	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab Tremelimumab in second-line of patients with advanced gastric cancer. *Digestive and Liver Disease*, **2021**, 53, 420-426	3.3	4
38	Infections in Patients with Chronic Granulomatous Disease Treated with Tumor Necrosis Factor Alpha Blockers for Inflammatory Complications. *Journal of Clinical Immunology*, **2021**, 41, 185-193	5.7	4
37	Inflammatory bowel disease after allogeneic stem cell transplantation. *Bone Marrow Transplantation*, **2015**, 50, 1365-6	4.4	3
36	Decreased tryptophan and increased kynurenine levels in mastocytosis associated with digestive symptoms. *Allergy: European Journal of Allergy and Clinical Immunology*, **2016**, 71, 416-20	9.3	3
35	SARS-CoV-2 vaccines and donor recruitment for FMT. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 264-266	18.8	3
34	Fecal Microbiota Transplantation for Ulcerative Colitis. *JAMA - Journal of the American Medical Association*, **2019**, 321, 2240	27.4	2

33	Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. *Trials*, **2020**, 21, 455	2.8	2
32	Nucleotide-Binding Domain Leucine-Rich Repeat Containing Proteins and Intestinal Microbiota: Pivotal Players in Colitis and Colitis-Associated Cancer Development. *Frontiers in Immunology*, **2018**, 9, 1039	8.4	2
31	Single immunoglobulin infusion can reverse hemodynamic failure associated with severe Clostridium difficile colitis. *American Journal of Gastroenterology*, **2009**, 104, 2649-50	0.7	2
30	AhR/IL-22 pathway as new target for the treatment of post-infectious irritable bowel syndrome symptoms.. *Gut Microbes*, **2022**, 14, 2022997	8.8	2
29	Circulating bile acids concentration is predictive of coronary artery disease in human. *Scientific Reports*, **2021**, 11, 22661	4.9	2
28	The enemy from within: a prophage ofRoseburia intestinalissystematically turns lytic in the mouse gut, driving bacterial adaptation by CRISPR spacer acquisition		2
27	Insights into the genetic epidemiology of Crohn and rare diseases in the Ashkenazi Jewish population		2
26	Antibiotics: a trigger for inflammatory bowel disease?. *The Lancet Gastroenterology and Hepatology*, **2020**, 5, 956-957	18.8	2
25	Sequencing of over 100,000 individuals identifies multiple genes and rare variants associated with Crohns disease susceptibility		2
24	Gut microbiota in PSC′: From association to possible causality. Commentary to "Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis" by Nakamoto et al., Nature Microbiology, January 2019. *Clinics and Research in Hepatology and Gastroenterology*, **2020**, 44, 123-125	2.4	2
23	Immune-mediated inflammatory diseases and nutrition: results from an online survey on patients' practices and perceptions. *BMC Nutrition*, **2021**, 7, 38	2.5	2
22	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. *Digestive and Liver Disease*, **2021**, 53, 1254-1259	3.3	2
21	Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases.. *Neurogastroenterology and Motility*, **2022**, e14320	4	1
20	Validation of the performance of A1HPV6, a triage blood test for the early diagnosis and prognosis of SARS-CoV-2 infection. **2022**,		1
19	Specificities of the intestinal microbiota in patients with inflammatory bowel disease and Clostridium difficile infection		1
18	Gut microbiome alterations in anti-NMDA receptor encephalitis: caveats for result interpretation. *Annals of Clinical and Translational Neurology*, **2020**, 7, 153-154	5.3	1
17	Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation. *Mucosal Immunology*, **2021**, 14, 1127-1132	9.2	1
16	Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. *Alimentary Pharmacology and Therapeutics*, **2020**, 52, 303-310	6.1	0

15	Human microbial metabolite mimicry as a strategy to expand the chemical space of potential drugs. *Drug Discovery Today*, **2020**, 25, 1575-1579	8.8	0
14	Body mass index and disease activity at treatment initiation: potential new predictors of response to azathioprine therapy in IBD. *Inflammatory Bowel Diseases*, **2010**, 16, 714-5	4.5	0
13	Impact of Aphthous Colitis at Diagnosis on Crohn's Disease Outcomes. *Journal of Crohnis and Colitis* , **2020**, 14, 342-350	1.5	0
12	Tofacitinib treatment alters mucosal immunity and gut microbiota during experimental arthritis. *Clinical and Translational Medicine*, **2020**, 10, e163	5.7	0
11	Mature CD8 T-cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. *Clinical Case Reports (discontinued)*, **2016**, 4, 1088-1090	0.7	0
10	Inflammatory Bowel Diseases: How to Identify High-Risk Patients **2017**, 653-660		
9	Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed. *United European Gastroenterology Journal*, **2020**, 8, 353-354	5.3	
8	Letter: not the end of the role of anti-viral therapy in ulcerative colitis with cytomegalovirus reactivation - authors' reply. *Alimentary Pharmacology and Therapeutics*, **2014**, 39, 1247-8	6.1	
7	Air mass pushing the liver. *Digestive and Liver Disease*, **2011**, 43, 1025	3.3	
6	Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea.. *BMC Microbiology*, **2022**, 22, 54	4.5	
5	The Gut Microbiome in Inflammatory Bowel Disease **2019**, 347-377		
4	Impact of Gut Mycobiota Composition on Outcomes after Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2019**, 134, 194-194	2.2	
3	How to Identify High-Risk Patients in Inflammatory Bowel Disease? **2012**, 713-725		
2	Arthrose et microbiote intestinal. *Revue Du Rhumatisme Monographies*, **2021**, 88, 92-96	0	
1	SER-109 for Recurrent Clostridioides difficile Infection.. *New England Journal of Medicine*, **2022**, 386, 1956-1957	59.2	